ZAI LAB LIMITED Earnings Per Share (Basic)
ZAI LAB LIMITED (ZLAB) reported Earnings Per Share (Basic) of -$0.05 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- ZAI LAB LIMITED earnings per share, basic for the quarter ending 2026-06-30 was -$0.05.
- ZAI LAB LIMITED earnings per share, basic for the quarter ending 2026-03-31 was -$0.05.
- ZAI LAB LIMITED earnings per share, basic for the quarter ending 2025-09-30 was -$0.03.
- ZAI LAB LIMITED earnings per share, basic for the quarter ending 2025-06-30 was -$0.04.
- ZAI LAB LIMITED earnings per share, basic for fiscal 2025 was -$0.16.
- ZAI LAB LIMITED earnings per share, basic for fiscal 2024 was -$0.26.
- ZAI LAB LIMITED earnings per share, basic for fiscal 2023 was -$0.35.
- ZAI LAB LIMITED earnings per share, basic for fiscal 2022 was -$0.46.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.05 10-Q · filed 2026-08-06 | -$0.09 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$0.05 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$0.16 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$0.03 10-Q · filed 2025-11-06 | -$0.11 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | -$0.04 10-Q · filed 2026-08-06 | -$0.08 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | -$0.04 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$0.26 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$0.04 10-Q · filed 2025-11-06 | -$0.18 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$0.08 10-Q · filed 2025-08-07 | -$0.14 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$0.05 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.35 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.07 10-Q · filed 2024-11-12 | -$0.20 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.25 10-Q · filed 2024-11-12 | -$0.31 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-06-30 | -$0.13 10-Q · filed 2024-08-06 | -$0.18 10-Q · filed 2024-08-06 | -$0.24 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.41 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-03-31 | -$0.05 10-Q · filed 2024-05-08 | -$0.12 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.28 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.43 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2022-12-31 | -$0.06 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.23 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.38 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.46 10-K · filed 2025-02-27 |
| 2022-09-30 | -$0.17 10-Q · filed 2023-11-07 | -$0.31 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$0.40 10-Q · filed 2023-11-07 | -$0.62 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2022-06-30 | -$0.14 10-Q · filed 2023-08-07 | -$0.23 10-Q · filed 2023-08-07 | -$0.45 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$0.55 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2022-03-31 | -$0.09 10-Q · filed 2023-05-09 | -$0.31 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$0.41 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$0.58 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2021-12-31 | -$0.22 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$0.32 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$0.50 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$0.76 10-K · filed 2024-02-27 |
| 2021-09-30 | -$0.10 10-Q · filed 2022-11-09 | -$0.28 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$0.53 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$0.18 10-Q · filed 2022-08-09 | -$0.44 10-Q · filed 2022-08-09 | ||
| 2020-12-31 | -$0.35 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |